BG107625A - Контрацептивен метод и форми за осъществяването му - Google Patents

Контрацептивен метод и форми за осъществяването му Download PDF

Info

Publication number
BG107625A
BG107625A BG107625A BG10762503A BG107625A BG 107625 A BG107625 A BG 107625A BG 107625 A BG107625 A BG 107625A BG 10762503 A BG10762503 A BG 10762503A BG 107625 A BG107625 A BG 107625A
Authority
BG
Bulgaria
Prior art keywords
phase
period
duration
receiving
inclusive
Prior art date
Application number
BG107625A
Other languages
Bulgarian (bg)
English (en)
Inventor
Hermann Kulmann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of BG107625A publication Critical patent/BG107625A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BG107625A 2000-09-14 2003-03-11 Контрацептивен метод и форми за осъществяването му BG107625A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045380A DE10045380A1 (de) 2000-09-14 2000-09-14 Verfahren zur Kontrazeption und dessen Darreichungsform
PCT/EP2001/010207 WO2002022110A2 (en) 2000-09-14 2001-09-05 Contraception process and administration form for the same

Publications (1)

Publication Number Publication Date
BG107625A true BG107625A (bg) 2003-11-28

Family

ID=7656125

Family Applications (2)

Application Number Title Priority Date Filing Date
BG107625A BG107625A (bg) 2000-09-14 2003-03-11 Контрацептивен метод и форми за осъществяването му
BG10111090A BG111090A (bg) 2000-09-14 2011-11-18 Контрацептивен процес и форми на приложение за същия

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG10111090A BG111090A (bg) 2000-09-14 2011-11-18 Контрацептивен процес и форми на приложение за същия

Country Status (32)

Country Link
US (2) US8076317B2 (de)
EP (2) EP2153849A3 (de)
JP (3) JP2004508398A (de)
KR (3) KR20090033502A (de)
CN (1) CN100560132C (de)
AR (1) AR030737A1 (de)
AT (1) ATE447972T1 (de)
AU (2) AU2001284052B2 (de)
BG (2) BG107625A (de)
BR (1) BR0113902A (de)
CA (1) CA2420292C (de)
CZ (1) CZ2003723A3 (de)
DE (2) DE10045380A1 (de)
EA (1) EA006875B1 (de)
EE (1) EE200300103A (de)
HK (1) HK1060305A1 (de)
HR (1) HRP20030294A2 (de)
HU (1) HUP0301042A3 (de)
IL (2) IL154521A0 (de)
ME (1) ME00291B (de)
MX (1) MXPA03002070A (de)
NO (1) NO20031152L (de)
NZ (1) NZ524448A (de)
PE (1) PE20020425A1 (de)
PL (1) PL361161A1 (de)
SK (1) SK3102003A3 (de)
TW (1) TWI297271B (de)
UA (1) UA93650C2 (de)
UY (1) UY26932A1 (de)
WO (1) WO2002022110A2 (de)
YU (1) YU19003A (de)
ZA (1) ZA200301359B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
AU2011226911B2 (en) * 2004-04-30 2014-06-19 Bayer Intellectual Property Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
GB0623813D0 (en) * 2006-11-29 2007-01-10 Stephenson Group Ltd Foam reduction
DE102007011486A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2140860A1 (de) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy Verbessertes Verhütungsverfahren
EP3936133A1 (de) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natürliche kombinationshormonersatzformulierungen und therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
ES2218556T3 (es) 1994-11-22 2004-11-16 Balance Pharmaceuticals, Inc. Metodos de contracepcion.
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR100518102B1 (ko) 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Also Published As

Publication number Publication date
HUP0301042A3 (en) 2010-03-29
CN1455681A (zh) 2003-11-12
CA2420292A1 (en) 2002-03-21
JP2013241456A (ja) 2013-12-05
WO2002022110A3 (en) 2002-07-04
US8536156B2 (en) 2013-09-17
PE20020425A1 (es) 2002-06-15
MXPA03002070A (es) 2003-06-24
IL154521A (en) 2014-05-28
KR20030031185A (ko) 2003-04-18
HUP0301042A2 (hu) 2003-10-28
EE200300103A (et) 2005-02-15
KR101240232B1 (ko) 2013-03-07
EP1317286A2 (de) 2003-06-11
SK3102003A3 (en) 2003-09-11
JP2013006866A (ja) 2013-01-10
UY26932A1 (es) 2001-12-28
EP2153849A3 (de) 2011-09-14
US8076317B2 (en) 2011-12-13
CZ2003723A3 (cs) 2003-06-18
EA006875B1 (ru) 2006-04-28
MEP37608A (en) 2011-02-10
EA200300338A1 (ru) 2003-08-28
WO2002022110A2 (en) 2002-03-21
AU8405201A (en) 2002-03-26
DE60140462D1 (de) 2009-12-24
KR20090033502A (ko) 2009-04-03
PL361161A1 (en) 2004-09-20
KR20100056577A (ko) 2010-05-27
AU2001284052B2 (en) 2006-11-30
HRP20030294A2 (en) 2005-02-28
CA2420292C (en) 2010-12-14
EP1317286B1 (de) 2009-11-11
NO20031152D0 (no) 2003-03-13
BR0113902A (pt) 2003-07-22
JP2004508398A (ja) 2004-03-18
NZ524448A (en) 2005-03-24
BG111090A (bg) 2012-03-30
YU19003A (sh) 2006-05-25
IL154521A0 (en) 2003-09-17
ATE447972T1 (de) 2009-11-15
TWI297271B (en) 2008-06-01
US20040219174A1 (en) 2004-11-04
AR030737A1 (es) 2003-09-03
US20120129823A1 (en) 2012-05-24
ME00291B (me) 2011-05-10
ZA200301359B (en) 2004-02-05
DE10045380A1 (de) 2002-04-04
EP2153849A2 (de) 2010-02-17
HK1060305A1 (en) 2004-08-06
UA93650C2 (ru) 2011-03-10
NO20031152L (no) 2003-05-14
CN100560132C (zh) 2009-11-18

Similar Documents

Publication Publication Date Title
BG107625A (bg) Контрацептивен метод и форми за осъществяването му
AU620940B2 (en) Contraception system and method
KR100186780B1 (ko) 피임제제
AU2001284052A1 (en) Contraception process and administration form for the same
AU725670B2 (en) Progestogen-anti-progestogen regimens
FI99083C (fi) Matalaestrogeenisia oraalisia raskaudenehkäisyvalmisteita
US3932635A (en) Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
JPH09502733A (ja) ホルモン避妊及び／又はざ瘡治療のための手段及び方法
US6506390B2 (en) Progestogen-anti-progestogen regimens
JPH0569810B2 (de)
JPH11508538A (ja) ホルモン避妊用薬剤の複合調剤、キット及び避妊方法
RU2004113305A (ru) Комбинированный эстрогенный/гестагенный препарат и его применение
PT1372665E (pt) Terapêutica de substituição hormonal e sua forma de administração
MXPA98010747A (en) Regimes of progestogeno-anti-progestog